Listed by the USPTO as LEE, WILLIAM Y
Tech Center 1600 • Art Units: 1623 1626 1629
This examiner grants 48% of resolved cases
LEE, WILLIAM Y is assigned to USPTO Tech Center 1600 and art unit 1623. The profile covers 714 resolved cases, with an allowance rate of 47.9% and a median of 1171 days to allowance. The interview lift is 34.3%.
The record reflects a docket where applicants may need sustained substantive engagement. The allowance rate supports careful claim positioning and evidence selection, while the positive interview lift makes examiner interviews a practical consideration when clarifying the technical distinction over the cited art. The median period indicates that prosecution planning should account for a lengthy timeline.
The leading companies are Sydnexis, Inc., Sage Therapeutics LLC, and Spruce Biosciences Inc. The leading firms are WILSON SONSINI GOODRICH & ROSATI, BakerHostetler, and Knobbe, Martens, Olson & Bear, LLP. Those associations may help counsel identify comparable matters for preparation.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17727519 | Method of Treating Colorectal Cancers Using a PKC Inhibitor | Final Rejection | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. |
| 18480409 | CDK4/6 INHIBITORS AS A TREATMENT FOR CLONAL HEMATOPOIESIS | Non-Final OA | Washington University |
| 18567952 | PESTICIDALLY ACTIVE DIAZINE-AMIDE COMPOUNDS | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18201882 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | Non-Final OA | Flagship Pioneering Innovations V, Inc. |
| 18237705 | COMPOSITIONS AND METHODS FOR IMPROVED TREATMENT OF PLATINUM-BASED CHEMOTHERAPEUTIC RESISTANT TUMORS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 18684808 | QUINACRINE AND DERIVATIVES THEREOF FOR TREATMENT OF VIRAL INFECTIONS | Non-Final OA | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 17923786 | Uses and Formulations of Cannabinoids | Non-Final OA | ADD Advanced Drug Delivery Technologies Ltd. |
| 18705084 | PIPERIDINYL INDOLE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF | Non-Final OA | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. |
| 17874522 | GLYCOLIC ACID PROTECTS AGAINST ISCHEMIC INSULTS | Non-Final OA | Individual inventor |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy47.9% of resolved applications examined by William Y Lee were allowed (714 resolved cases), compared with 51.0% across Art Unit 1623 over the last five years.
This examiner's interview lift is +34.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by William Y Lee took 1,171 days on average from filing to allowance.
William Y Lee examines applications in Art Unit 1623 in Tech Center 1600 (Biotechnology & Pharmaceuticals).